Lipocine Inc. (NASDAQ:LPCN)’s share price traded down 5% on Tuesday . The stock traded as low as $4.13 and last traded at $4.14, with a volume of 72,786 shares changing hands. The stock had previously closed at $4.36.

Separately, Canaccord Genuity restated a “buy” rating and set a $6.00 price objective on shares of Lipocine in a research report on Wednesday, August 10th.

The firm’s market capitalization is $73.21 million. The firm’s 50-day moving average is $3.65 and its 200-day moving average is $8.07.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.05. Equities research analysts expect that Lipocine Inc. will post ($1.31) earnings per share for the current year.

An institutional investor recently raised its position in Lipocine stock. Dimensional Fund Advisors LP increased its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 73.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 271,272 shares of the specialty pharmaceutical company’s stock after buying an additional 114,448 shares during the period. Dimensional Fund Advisors LP owned 1.49% of Lipocine worth $3,508,000 as of its most recent SEC filing.

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.